Company earnings

NMRA Earnings Date & History

Neumora Therapeutics Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.

Last updated Aug 19, 2026 at 7:33 PM ET

Neumora Therapeutics Inc

Pharmaceuticals

Next earnings date
Not scheduled
Reporting session
EPS estimate
Revenue estimate

NMRA earnings history

Report dateQuarterEPS est.EPS actualSurpriseRevenue
Thursday, May 7, 2026Q1 2026$-0.32$-0.30+5.1%$0
Monday, March 30, 2026Q4 2025$-0.33$-0.35-5.4%$0
Thursday, November 6, 2025Q3 2025$-0.34$-0.32+6.0%$0
Wednesday, August 6, 2025Q2 2025$-0.38$-0.33+12.2%$0

What the market is watching in NMRA's next report

  • The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
  • Ticker Read combines trend, relative strength and catalysts in one research view.
  • Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Free by email

Get the week's earnings by email

One free email each week: the reports that matter, when they land, and what the market is watching.

No account required. Unsubscribe any time. Research and education only — not investment advice.

Frequently asked questions

When is the next NMRA earnings date?
Neumora Therapeutics Inc has not confirmed its next reporting date yet. This page updates automatically once the date is scheduled.
Does NMRA report before or after the market?
The reporting session is published with the confirmed date; recent quarters are listed in the history table on this page.
What EPS is expected for NMRA?
Analyst estimates for the upcoming quarter have not been published yet.

Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.

NMRA earnings discussion

Anyone can read. Any free Hyper Stocks account can join in.

Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.

Loading discussion…

Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.